Drug Delivery of siRNA Therapeutics

The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for g...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Format: Online
Jezik:engleski
Izdano: MDPI - Multidisciplinary Digital Publishing Institute 2021
Teme:
Online pristup:ONIX_20210501_9783039362004_349
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
_version_ 1869516692858601472
collection Directory of Open Access Books
description The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs.
format Online
id doab-20.500.12854ir-68603
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-686032024-03-30T23:21:56Z Drug Delivery of siRNA Therapeutics Lamberti, Gaetano Angela Barba, Anna oligonucleotide delivery light-activated release intracellular release liposome indocyanine green drug co-delivery methotrexate siRNA antitumor effect mixed micelles targeted delivery system cationic liposome folate folate receptor cationic cholesterol derivative siRNA delivery gene knockdown tumor-targeting VEGFA VEGFR1 endoglin peptide angiogenesis gene silencing migration proliferation endothelial cells RNAi therapeutics amphiphilic dendrons PAMAM dendrimers self-assembling nanovectors covalent dendrimers NABDs liposomes clinical trials drug delivery nanoparticle carbonate apatite ERBB2 AKT breast cancer ovarian cancer polymer lipid delivery poly(ethylene) imine PEI RNA tyrosine-modification tumor xenograft magnetic nanoparticle iron oxide BCL2 BIRC5/survivin oral cancer aptamers cancer nanoparticles STAT6 polyaspartamide pegylation polyamine polyplexes asthma n/a thema EDItEUR::M Medicine and Nursing The new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs. 2021-05-01T15:15:38Z 2021-05-01T15:15:38Z 2020 book ONIX_20210501_9783039362004_349 9783039362004 9783039362011 https://directory.doabooks.org/handle/20.500.12854/68603 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2365 https://mdpi.com/books/pdfview/book/2365 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03936-201-1 10.3390/books978-3-03936-201-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039362004 9783039362011 288 Basel, Switzerland open access
spellingShingle oligonucleotide delivery
light-activated release
intracellular release
liposome
indocyanine green
drug co-delivery
methotrexate
siRNA
antitumor effect
mixed micelles
targeted delivery system
cationic liposome
folate
folate receptor
cationic cholesterol derivative
siRNA delivery
gene knockdown
tumor-targeting
VEGFA
VEGFR1
endoglin
peptide
angiogenesis
gene silencing
migration
proliferation
endothelial cells
RNAi therapeutics
amphiphilic dendrons
PAMAM dendrimers
self-assembling
nanovectors
covalent dendrimers
NABDs
liposomes
clinical trials
drug delivery
nanoparticle
carbonate apatite
ERBB2
AKT
breast cancer
ovarian cancer
polymer
lipid
delivery
poly(ethylene) imine
PEI
RNA
tyrosine-modification
tumor xenograft
magnetic nanoparticle
iron oxide
BCL2
BIRC5/survivin
oral cancer
aptamers
cancer
nanoparticles
STAT6
polyaspartamide
pegylation
polyamine
polyplexes
asthma
n/a
thema EDItEUR::M Medicine and Nursing
Drug Delivery of siRNA Therapeutics
title Drug Delivery of siRNA Therapeutics
title_full Drug Delivery of siRNA Therapeutics
title_fullStr Drug Delivery of siRNA Therapeutics
title_full_unstemmed Drug Delivery of siRNA Therapeutics
title_short Drug Delivery of siRNA Therapeutics
title_sort drug delivery of sirna therapeutics
topic oligonucleotide delivery
light-activated release
intracellular release
liposome
indocyanine green
drug co-delivery
methotrexate
siRNA
antitumor effect
mixed micelles
targeted delivery system
cationic liposome
folate
folate receptor
cationic cholesterol derivative
siRNA delivery
gene knockdown
tumor-targeting
VEGFA
VEGFR1
endoglin
peptide
angiogenesis
gene silencing
migration
proliferation
endothelial cells
RNAi therapeutics
amphiphilic dendrons
PAMAM dendrimers
self-assembling
nanovectors
covalent dendrimers
NABDs
liposomes
clinical trials
drug delivery
nanoparticle
carbonate apatite
ERBB2
AKT
breast cancer
ovarian cancer
polymer
lipid
delivery
poly(ethylene) imine
PEI
RNA
tyrosine-modification
tumor xenograft
magnetic nanoparticle
iron oxide
BCL2
BIRC5/survivin
oral cancer
aptamers
cancer
nanoparticles
STAT6
polyaspartamide
pegylation
polyamine
polyplexes
asthma
n/a
thema EDItEUR::M Medicine and Nursing
topic_facet oligonucleotide delivery
light-activated release
intracellular release
liposome
indocyanine green
drug co-delivery
methotrexate
siRNA
antitumor effect
mixed micelles
targeted delivery system
cationic liposome
folate
folate receptor
cationic cholesterol derivative
siRNA delivery
gene knockdown
tumor-targeting
VEGFA
VEGFR1
endoglin
peptide
angiogenesis
gene silencing
migration
proliferation
endothelial cells
RNAi therapeutics
amphiphilic dendrons
PAMAM dendrimers
self-assembling
nanovectors
covalent dendrimers
NABDs
liposomes
clinical trials
drug delivery
nanoparticle
carbonate apatite
ERBB2
AKT
breast cancer
ovarian cancer
polymer
lipid
delivery
poly(ethylene) imine
PEI
RNA
tyrosine-modification
tumor xenograft
magnetic nanoparticle
iron oxide
BCL2
BIRC5/survivin
oral cancer
aptamers
cancer
nanoparticles
STAT6
polyaspartamide
pegylation
polyamine
polyplexes
asthma
n/a
thema EDItEUR::M Medicine and Nursing
url ONIX_20210501_9783039362004_349